收费全文 | 2614篇 |
免费 | 143篇 |
国内免费 | 23篇 |
耳鼻咽喉 | 28篇 |
儿科学 | 46篇 |
妇产科学 | 71篇 |
基础医学 | 360篇 |
口腔科学 | 88篇 |
临床医学 | 237篇 |
内科学 | 682篇 |
皮肤病学 | 58篇 |
神经病学 | 339篇 |
特种医学 | 106篇 |
外科学 | 240篇 |
综合类 | 8篇 |
预防医学 | 113篇 |
眼科学 | 32篇 |
药学 | 166篇 |
中国医学 | 2篇 |
肿瘤学 | 204篇 |
2023年 | 16篇 |
2022年 | 26篇 |
2021年 | 74篇 |
2020年 | 55篇 |
2019年 | 72篇 |
2018年 | 92篇 |
2017年 | 69篇 |
2016年 | 59篇 |
2015年 | 69篇 |
2014年 | 94篇 |
2013年 | 124篇 |
2012年 | 179篇 |
2011年 | 157篇 |
2010年 | 77篇 |
2009年 | 72篇 |
2008年 | 168篇 |
2007年 | 143篇 |
2006年 | 135篇 |
2005年 | 131篇 |
2004年 | 122篇 |
2003年 | 147篇 |
2002年 | 120篇 |
2001年 | 75篇 |
2000年 | 85篇 |
1999年 | 49篇 |
1998年 | 32篇 |
1997年 | 26篇 |
1996年 | 18篇 |
1995年 | 18篇 |
1994年 | 14篇 |
1993年 | 13篇 |
1992年 | 34篇 |
1991年 | 31篇 |
1990年 | 24篇 |
1989年 | 18篇 |
1988年 | 11篇 |
1987年 | 20篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1981年 | 5篇 |
1979年 | 7篇 |
1975年 | 4篇 |
1974年 | 6篇 |
1970年 | 5篇 |
1969年 | 3篇 |
1968年 | 4篇 |
1967年 | 3篇 |
1966年 | 9篇 |
Previous studies have reported that statin or ezetimibe therapy has an anti-inflammatory effect. However, the results of individual studies on the effect of statin therapy in combination with ezetimibe on C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels have not been clear. Therefore, the present systematic review and meta-analysis were conducted on randomized clinical trials (RCTs) to evaluate the effect of statin therapy in combination with ezetimibe on CRP and hs-CRP levels.
MethodsA literature search was carried out on the MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases up to February 2022 to find eligible studies. The pooled effect sizes were considered for weighted mean difference (WMD) and 95% confidence intervals (CI) for CRP and hs-CRP, and it was also determined as standardized weighted mean difference (SMD) for overall CRP. For all variables, a random-effects model was used.
ResultsOf the 57 studies included in the systematic review, 53 were used for meta-analysis. Statin therapy in combination with ezetimibe significantly reduced the serum levels of hs-CRP (WMD ??0.2 mg/l; 95% CI ??0.4, ??0.1, P???0.001) and overall CRP (SMD ??0.16 mg/l; 95% CI ??0.2, ??0.07, P???0.001). Nevertheless, CRP levels were not significantly changed by combination therapy. A significant association was observed between the serum low-density lipoprotein cholesterol (LDL-C) changes and hs-CRP levels, which can justify the source of heterogeneity.
ConclusionsThe current study showed that statin therapy in combination with ezetimibe could be effective in reducing the levels of hs-CRP and overall CRP.
Graphical abstract 相似文献Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached.
When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06).
The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively).
In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible. 相似文献